EpLink is requesting input from BC pharmacists to help shape a national epilepsy research agenda
[Updated - January 26, 2020]
A new coronavirus is causing respiratory infections mostly in Wuhan, China. The risk to British Columbians is considered low
This year UBC’s Continuing Pharmacy Professional Development (CPPD) celebrates its 31st annual Update Conference.
This CPPD Conference will allow pharmacy professionals and all health care providers to enhance and update their knowledge and skills. In doing so, attendees will be able to improve patient care, medication management, and public safety.
Guest Post: New Requirements to Report Serious Adverse Drug Reactions and Medical Device Incidents to Health Canada Coming into Effect Soon
On December 16, 2019, new federal regulations, associated with the Protecting Canadians from Unsafe Drugs Act (also known as Vanessa’s Law), will come into effect requiring hospitals across the country to report serious adverse drug reactions (ADRs) and medical device incidents (MDIs) to Health Canada within 30 days of being documented within the hospital.
Guest Post: Recognizing Pharmacist Practice Educators as Important Partners in Teaching Safe Patient Care
To acknowledge the important role that our practice educators play in teaching and supervising students, the Pharmacy Practice Educator of the Year Awards (2018/2019) were presented at the annual Celebrate the Pharmacy Practice Educator, Facilitator, and Community Partner Appreciation Event on October 22, 2019 at the Delta Hotels Burnaby Conference Centre in Burnaby, BC.
The Canadian Council on Continuing Education in Pharmacy is asking for BC’s pharmacy professionals to participate in a survey to help inform their new strategic plan
Zuclopenthixol decanoate is a first generation depot antipsychotic available in Canada in 200mg /ml solution for injection (ampoule). It is usually simply known by its brand name ClopixolR. It is used for maintenance treatment of schizophrenia or psychosis.
A review of pharmacy’s most common patient-induced therapeutic errors and how pharmacists can help avoid them by the BC Drug and Poison Information Centre.
Call for Abstracts is now OPEN!
Abstract submission deadline: September 13, 2019
Recently, a decision was made by the Ministry of Health to provide coverage for the commercially available Metadol-D product (DIN 2244290) as an alternative for patients in the community who cannot take or are not benefiting from Methadose. As of May 28, 2019, Metadol-D (10mg/mL) is eligible for regular benefit coverage through PharmaCare.